ArticleScientific reports2025
Association of pulse pressure with presynaptic dysfunction in older adults with Alzheimer's disease: a cohort study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pulse pressure as a predictor of Alzheimer's disease biomarkers and cognitive decline: The moderating role of APOE ε4.The journal of prevention of Alzheimer's disease · 2025Trial
- Vascular stiffness predicts plasma markers of neurodegeneration among older African Americans.The journal of prevention of Alzheimer's disease · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Vascular aging and synaptic dysfunction are closely related to Alzheimer's disease (AD) pathology, but the link between the two remains unclear. We aimed to investigate the relationship among pulse pressure (PP), presynaptic dysfunction, and in vivo AD pathologies, including amyloid beta (Aβ) deposition and cerebrospinal fluid (CSF) phosphorylated tau (p-tau). A total of 649 older adults, both cognitively normal and with mild cognitive impairment, were recruited from the Alzheimer's Disease Neuroimaging Initiative database. We investigated the associations of PP with CSF GAP-43, a marker of presynaptic dysfunction, and CSF p-tau. The mediation effect of presynaptic dysfunction on the association between PP and CSF p-tau was also examined. Elevated PP was significantly associated with greater presynaptic dysfunction (unstandardized B = 26.774, 95% confidence interval (CI) [12.102, 41.447], t = 3.583, p < 0.001) and elevated levels of CSF p-tau (B = 0.102, 95% CI [0.037, 0.168], t = 3.093, p = 0.002) and total tau (B = 0.927, 95% CI [0.331, 1.524], t = 3.052, p = 0.002). A positive interaction between PP and cortical Aβ deposition (F = 12.752, p < 0.001) indicated that PP resulted in severe presynaptic dysfunction as Aβ deposition increased. Further analyses revealed that presynaptic dysfunction mediated the association between PP and CSF p-tau. PP had no significant direct effect but had a significant indirect effect (81.6% of the total) on CSF p-tau. Elevated PP exacerbated presynaptic dysfunction in nondemented older adults, particularly those with AD pathology, and can lead to tau pathology. Further research on the mechanism underlying the relationship between PP and presynaptic dysfunction is warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.